The European Medicines Agency (EMA) is will be moving its offices from London to Amsterdam, due to the UK’s decision to withdraw from the European Union. According to a press release issued by the EMA, the relocation effort needs to be completed by the end of March 2019.
This guide analyzes how artificial intelligence – including machine learning – can be used by pharmaceutical and medical device companies to improve the clinical data review and cleansing process.
The EMA currently employs close to 900 people, a majority of who have said they would be willing to move to Amsterdam. Nonetheless, the regulatory agency acknowledged that “activities will be impacted and we need to plan for this now to avoid the creation of gaps in knowledge and expertise.” A business continuity plan (BCP), which was published on September 26, 2017, indicates that it is prepared to handle a situation in which staff losses are significant.
Click here to read the press release.